Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry

0533351 - ÚI 2022 RIV IT eng J - Journal Article
Renda, G. - Pecen, Ladislav - Patti, G. - Ricci, F. - Kotecha, D. - Siller-Matula, J. M. - Schnabel, R. B. - Wachter, R. - Sellal, J.-M. - Rohla, M. - Lucerna, M. - Huber, K. - Verheugt, F. W. A. - Zamorano, J. - Brüggenjürgen, B. - Darius, H. - Duytschaever, M. - Le Heuzey, J.Y. - Schilling, R. J. - Kirchhof, P. - De Caterina, R.
Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry.
Internal and Emergency Medicine. Roč. 16, č. 3 (2021), s. 591-599. ISSN 1828-0447. E-ISSN 1970-9366
Institutional support: RVO:67985807
Keywords : Anticoagulants * Atrial fibrillation * Bleeding * Major cardiac or cerebrovascular events * NOAC * Registry
OECD category: Cardiac and Cardiovascular systems
Impact factor: 5.472, year: 2021
Method of publishing: Open access

The management of patients with atrial fibrillation (AF) has rapidly changed with increasing use of non-vitamin K antagonist oral anticoagulants (NOACs) and changes in the use of rhythm control therapy. The prevention of thromboembolic events European Registry in Atrial Fibrillation Prolongation Registry (PREFER Prolongation) enrolled consecutive patients with AF on NOACs between 2014 and 2016 in a multicentre, prospective, observational study with one-year follow-up, focusing on the time of introduction of NOACs. Overall, 3783 patients were enrolled, with follow-up information available in 3223 (85%). Mean age was 72.2 ± 9.4 years, 40% were women, mean CHA2DS2VASc score was 3.4 ± 1.6, and 2587 (88.6%) had a CHA2DS2VASc score ≥ 2. Rivaroxaban was used in half of patients, and dabigatran and apixaban were used in about a quarter of patients each, edoxaban was not available for use in Europe at the time. Major cardiovascular event rate was low: serious events occurred in 74 patients (84 events, 2%), including 24 strokes (1%), 62 major bleeds (2%), of which 30 were life-threatening (1%) and 3 intracranial (0.1%), and 28 acute coronary syndromes (1%). Mortality was 2%. Antiarrhythmic drugs were used in about 50% of patients, catheter ablation in 5%. Adverse events were low in this contemporary European cohort of unselected AF patients treated with NOACs already at the time of their first introduction, despite high thromboembolic risk.
Permanent Link: http://hdl.handle.net/11104/0311757